Everest Medicines Limited (HKG: 1952) has entered into an asset acquisition agreement with Corxel Pharmaceuticals Limited (CORXEL) to secure development, commercialization, and localized production rights for Etripamil nasal spray (US: CARDAMYST) in Greater China – a USD 50 million transaction that delivers the first FDA‑approved acute PSVT therapy in over 30 years to Everest’s cardiovascular portfolio ahead of anticipated NMPA approval in Q3 2026.
No approved acute PSVT pharmacotherapy in China; off‑label calcium channel blocker use
First‑in‑class positioning with 5‑7 year market exclusivity potential
Everest Portfolio Fit
Adds cardiovascular/rare disease asset to infectious disease and oncology focus
Diversification into high‑value acute care; leverages hospital/GI relationships
Commercial Outlook
China PSVT Market Dynamics: Estimated 1.5‑2 million diagnosed PSVT patients in China; acute episode frequency 2‑4 episodes/patient/year; addressable market RMB2‑3 billion annually assuming 30‑40% patient penetration and RMB300‑500 per episode pricing; Etripamil’s home‑use positioning supports premium pricing vs. generic off‑label alternatives.
Everest Execution Advantage: Acquisition of NDA‑stage asset (vs. early‑development licensing) de‑risks timeline and investment; Q3 2026 NMPA approval enables H2 2026 launch with immediate revenue recognition; localized production rights support cost optimization and supply security vs. import dependency.
Corxel Exit Rationale: USD 50 million monetization of licensed‑in asset (originally from Milestone Pharma) provides return on 4‑year development investment; Corxel likely retains other pipeline assets or focuses on core therapeutic areas.
Milestone Pharma Partnership: Original US developer (NASDAQ: MIST) retains ex‑Greater China rights; Everest acquisition validates China market attractiveness for US biotech; potential for regulatory synergy (FDA approval supports NMPA review) and physician education collaboration.
Competitive Defensibility: 30‑year innovation gap in PSVT acute therapy creates first‑mover advantage; nasal spray formulation complexity (device + formulation) provides manufacturing barrier to entry; Everest’s 5‑year exclusivity (orphan drug designation potential) supports sustainable returns.
Forward‑Looking Statements This brief contains forward‑looking statements regarding NMPA approval timelines, commercialization expectations, and market penetration projections for Etripamil in Greater China. Actual results may differ due to regulatory review outcomes, manufacturing scale‑up challenges, and competitive dynamics in the cardiovascular therapeutics market.-Fineline Info & Tech
